Aktuelle smitsomme sygdomme
Søgeord (hepatitis) valgt.
88 emner vises.
Mira Hleyhel, Julia Geller, Amal Sadou, Paul Naaber, Tatiana Kuznetsova, Sigrid Vorobjov, Marleen Lõhmus, Martina Furegato, Suzanne Reed, Benjamin Bluemel, Erika Duffell and Kristi Rüütel
Eurosurveillance latest updates, 26.07.2024
Tilføjet 26.07.2024
IntroductionObtaining epidemiological data on chronic hepatitis C virus (HCV) infection is essential to monitor progress towards the hepatitis C elimination targets. AimWe aimed to estimate the prevalence of chronic HCV and the seroprevalence of HCV in the adult general population in Estonia. MethodsThis cross-sectional study, conducted between 12 July and 6 December 2022, included anonymised residual sera collected prospectively from patients 18 years and older visiting a general practitioner in all counties of Estonia. Specimens were considered HCV-seropositive if they tested positive for HCV antibodies by enzyme-linked immunoassay, confirmed by line-immunoblot assay. Chronic HCV infection was determined by positive RT-qPCR. ResultsWe tested a total of 4,217 specimens. The estimated HCV seroprevalence and prevalence of chronic HCV infection were 1.8% (95% CI: 1.4–2.2) and 0.8% (95% CI: 0.5–1.1), respectively, with ca 8,100 persons estimated to have chronic HCV infection in the general adult population of Estonia. No statistically significant differences in the prevalence of chronic HCV infection were observed between sexes, counties or age groups, with the highest prevalence rates observed in men (sex ratio: 1.7), Ida-Virumaa County (1.8%; 95% CI: 0.8–3.6) and the age group 40–49 years (1.7%; 95% CI: 0.9–2.9). ConclusionThis study found an overall low prevalence of chronic HCV infection in Estonia. Continued efforts should be made for the targeted screening, diagnosis and treatment of individuals with chronic HCV infection to achieve hepatitis elimination targets.
Læs mereMira Hleyhel, Odette Popovici, Mihaela Leuștean, Suzanne Reed, Amal Sadou, Martina Furegato, Benjamin Bluemel, Erika Duffell and Otilia Mardh
Eurosurveillance latest updates, 26.07.2024
Tilføjet 26.07.2024
IntroductionA national study from 2006 to 2008 showed a high antibody prevalence of 3.2% against hepatitis C virus (HCV) in Romania, but more recent epidemiological data on hepatitis C prevalence are lacking. AimWe aimed to estimate the current prevalence of HCV antibodies (anti-HCV) and chronic HCV infection in the general adult population in Romania, as a crucial element in monitoring progress towards eliminating hepatitis C. MethodsWe used anonymised leftover sera from a SARS-CoV-2 survey conducted between July and October 2020 (n = 2,100), supplemented with sera collected prospectively between July 2022 and March 2023 (n = 574). These included sera collected from adults visiting laboratories for routine medical check-ups. Sera were tested for anti-HCV and HCV core antigen and classified according to anti-HCV and chronic infection status. ResultsOf the total 2,674 specimens tested, 44 were anti-HCV-positive with a weighted anti-HCV prevalence of 1.4% (95% CI: 1.0–1.9), and 29 were HCV core antigen-positive with a weighted prevalence of chronic infection of 0.9% (95% CI: 0.5–1.2). The prevalence of chronic infection did not differ significantly between men and women. It was higher in persons 60 years and older (2.0%; 95% CI: 1.1–3.0) and in specimens from the North-East region (2.2%; 95% CI: 0.8–3.7). ConclusionAlthough the overall HCV prevalence in Romania is currently low, targeted screening, prevention measures and treatment scale-up are needed especially for the population 60 years and older and in the north-eastern part of the country to achieve the goal of ending the hepatitis C epidemic.
Læs mereMojca Matičič and Maria Buti
Eurosurveillance latest updates, 26.07.2024
Tilføjet 26.07.2024
Morbidity and Mortality Weekly Report (MMWR), 25.07.2024
Tilføjet 25.07.2024
Pablo Ryan, Jorge Valencia, Guillermo Cuevas, Rafael Amigot-Sanchez, Isidoro Martínez, Jeffrey V Lazarus, Felipe Pérez-García and Salvador Resino
Eurosurveillance latest updates, 20.07.2024
Tilføjet 20.07.2024
BackgroundPeople who use drugs (PWUD) are a key target population to reduce the burden of hepatitis C virus (HCV) infection. AimTo assess risk factors and temporal trends of active HCV infection in PWUD in Madrid, Spain. MethodsWe conducted a retrospective study between 2017 and 2023, including 2,264 PWUD visiting a mobile screening unit. Data about epidemiology, substance use and sexual risk behaviour were obtained through a 92-item questionnaire. HCV was detected by antibody test, followed by RNA test. The primary outcome variable was active HCV infection prevalence, calculated considering all individuals who underwent RNA testing and analysed by logistic regression adjusted by the main risk factors. ResultsOf all participants, 685 tested positive for anti-HCV antibodies, and 605 underwent RNA testing; 314 had active HCV infection, and 218 initiated treatment. People who inject drugs (PWID) were identified as the main risk group. The active HCV infection rate showed a significant downward trend between 2017 and 2023 in the entire study population (23.4% to 6.0%), among PWID (41.0% to 15.0%) and PWUD without injecting drug use (7.0% to 1.3%) (p
Læs mereMielle Abbott, Jennifer H MacLachlan, Nicole Romero, Nicole Matthews, Nasra Higgins, Alvin Lee, Mark Stoove, Tafireyi Marukutira, Brendan Quinn, Nicole L Allard and Benjamin C Cowie
Eurosurveillance latest updates, 20.07.2024
Tilføjet 20.07.2024
BackgroundActive follow-up of chronic hepatitis C notifications to promote linkage to care is a promising strategy to support elimination. AimThis pilot study in Victoria, Australia, explored if the Department of Health could follow-up on hepatitis C cases through their diagnosing clinicians, to assess and support linkage to care and complete data missing from the notification. MethodsFor notifications received between 1 September 2021 and 31 March 2022 of unspecified hepatitis C cases (i.e. acquired > 24 months ago or of unknown duration), contact with diagnosing clinicians was attempted. Data were collected on risk exposures, clinical and demographic characteristics and follow-up care (i.e. HCV RNA test; referral or ascertainment of previous negative testing or treatment history). Reasons for unsuccessful doctor contact and gaps in care provision were investigated. Advice to clinicians on care and resources for clinical support were given on demand. ResultsOf 513 cases where information was sought, this was able to be obtained for 356 (69.4%). Reasons for unsuccessful contact included incomplete contact details or difficulties getting in touch across three attempts, particularly for hospital diagnoses. Among the 356 cases, 307 (86.2%) had received follow-up care. Patient-management resources were requested by 100 of 286 contacted diagnosing clinicians. ConclusionsMost doctors successfully contacted had provided follow-up care. Missing contact information and the time taken to reach clinicians significantly impeded the feasibility of the intervention. Enhancing system automation, such as integration of laboratory results, could improve completeness of notifications and support further linkage to care where needed.
Læs mereRicarda Plümers, Jens Dreier, Cornelius Knabbe, André Gömer, Eike Steinmann, Daniel Todt and Tanja Vollmer
Eurosurveillance latest updates, 14.06.2024
Tilføjet 14.06.2024
BackgroundAwareness of transfusion-transmitted hepatitis E raised in recent years led to the mandatory testing of blood donations in some European countries for hepatitis E virus (HEV) RNA. However, little is known about the epidemiology of HEV infections. AimTo and describe and analyse the epidemiology of HEV infections in blood donors in Germany. MethodsData from routine testing of therapeutic blood products donated between January 2015 and December 2022 at the Uni.Blutspendedienst OWL were analysed at the Institute of Laboratory and Transfusion Medicine, Heart and Diabetes Centre North Rhine-Westphalia. A total of 731,630 allogenic blood donations from 119,610 individual blood donors were tested for HEV RNA in minipools of 96 samples. The HEV RNA-positive donations were analysed for the presence of anti-HEV IgM and IgG. The HEV strains were genotyped and various clinical liver-specific parameters were determined. ResultsA total of 497 HEV-positive blood donations were identified, resulting in a yearly incidence of 1:1,474, from which 78.4% of the donations were RNA-only positive. Increased alanine aminotransferase activity was determined in 26.6% of HEV RNA-positive donors and was associated with the detection of IgG antibodies (1.2% anti-HEV IgM-positive, 11.9% anti-HEV IgM- and IgG-positive and 8.5% anti-HEV IgG-positive). An average incidence of 0.084–0.083% HEV RNA-positive donations in June and July in all years was observed, and a higher proportion of HEV RNA-positive men compared with women. All isolated HEV sequences corresponded to genotype 3. ConclusionOur results underline the necessity of HEV RNA screening in blood donations.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 31.05.2024
Tilføjet 31.05.2024
This report describes hepatitis C viral clearance proportions among people with hepatitis C by state.
Læs mereEbba Rosendal, Sebastian von Schreeb, Alexandre Gomes, Sara Lino, Berta Grau-Pujol, Sara Magalhães, Vasco Ricoca Peixoto, Carla Roque, Joana Moreno, Fernando Maltez, Fernando Almeida, Rita Sá Machado, Rui Tato Marinho, Paula Vasconcelos, Rita de Sousa and João Vieira Martins
Eurosurveillance latest updates, 26.05.2024
Tilføjet 26.05.2024
An outbreak of hepatitis A is ongoing in Portugal, with 71 confirmed cases from 7 October 2023 to 24 April 2024. Most cases are male, aged 18–44 years, with many identifying as men who have sex with men (MSM) and reported as suspected sexual transmission. Phylogenetic analysis identified the subgenotype IA, VRD 521–2016 strain, last observed in an MSM-associated multi-country outbreak in 2016 to 2018. We wish to alert colleagues in other countries to investigate potential similar spread.
Læs mereEbba Rosendal, Sebastian von Schreeb, Alexandre Gomes, Sara Lino, Berta Grau-Pujol, Sara Magalhães, Vasco Ricoca Peixoto, Carla Roque, Joana Moreno, Fernando Maltez, Fernando Almeida, Rita Sá Machado, Rui Tato Marinho, Paula Vasconcelos, Rita de Sousa and João Vieira Martins
Eurosurveillance latest updates, 24.05.2024
Tilføjet 24.05.2024
An outbreak of hepatitis A is ongoing in Portugal, with 71 confirmed cases from 7 October 2023 to 24 April 2024. Most cases are male, aged 18–44 years, with many identifying as men who have sex with men (MSM) and reported as suspected sexual transmission. Phylogenetic analysis identified the subgenotype IA, VRD 521–2016 strain, last observed in an MSM-associated multi-country outbreak in 2016 to 2018. We wish to alert colleagues in other countries to investigate potential similar spread.
Læs mereMedscape Infectious Diseases, 15.05.2024
Tilføjet 15.05.2024
The U.S. drug regulator has declined to approve expanded use of Dynavax Technologies\' hepatitis B vaccine in a section of patients, citing insufficient data over destruction... Reuters Health Information
Læs mereMedscape Infectious Diseases, 24.04.2024
Tilføjet 24.04.2024
Although annual incidence decreased from 2.5 million in 2019 to 2.2 million in 2022, the WHO considers it to be high. Medscape Medical News
Læs mereMedscape Infectious Diseases, 8.04.2024
Tilføjet 8.04.2024
While the hepatitis E virus causes tens of thousands of deaths each year, data suggest that a vaccine approved in China has long-term efficacy. Medscape Medical News
Læs mereECDC
ECDC COVID-19 updates, 22.03.2024
Tilføjet 22.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
Læs mereECDC
ECDC Communicable Disease Threats Report, 22.03.2024
Tilføjet 22.03.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 17-23 March 2024 and includes updates on SARS-CoV-2 variant classification, hepatitis A, pertussis, invasive Group A streptococcal infection, chikungunya, dengue, poliomyelitis, western equine encephalitis and cholera.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 16.02.2024
Tilføjet 16.02.2024
This report describes Correctional Health Services and LA County Jail\'s response to a confirmed case of Hepatitis A in a person who is incarcerated.
Læs mereECDC
ECDC Communicable Disease Threats Report, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mereECDC
ECDC COVID-19 updates, 9.02.2024
Tilføjet 9.02.2024
This issue of the ECDC Communicable Disease Threats Report (CDTR) the period 4-10 February 2024 and includes updates on avian influenza, measles, MERS-CoV, COVID-19, swine influenza, respiratory virus epidemiology, Western equine encephalitis, Hepatitis E, and the Chinese New Year.
Læs mereECDC
ECDC COVID-19 updates, 23.12.2023
Tilføjet 23.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
Læs mereECDC
ECDC Communicable Disease Threats Report, 22.12.2023
Tilføjet 22.12.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 17-23 December 2023 and includes updates on cholera, SARS-CoV-2 variant classification, avian influenza in fur farms, hepatitis A, pertussis, a cluster of extensively drug-resistant Shigella Sonnei among men who have sex with men, and an overview of respiratory virus epidemiology in the EU/EE.
Læs mereMedscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
At least 450 patients at Mass General Brigham, Salem Hospital, near Boston are at risk of HIV and hepatitis infection, according to a lawsuit claiming negligent intravenous medication administration. Medscape Medical News
Læs mereMedscape Infectious Diseases, 11.11.2023
Tilføjet 11.11.2023
A scientist whose work was key to identifying, studying, and finding treatments for this life-threatening virus discusses the scientific journey and challenges that persist. Knowable Magazine
Læs mereMorbidity and Mortality Weekly Report (MMWR), 1.11.2023
Tilføjet 1.11.2023
CDC reports on CDC recommendations for hepatitis C testing among perinatally exposed infants and children in the United States in 2023.
Læs mereMedscape Infectious Diseases, 20.10.2023
Tilføjet 20.10.2023
Despite ongoing hostilities, healthcare professionals take mobile clinics to their fellow Ukrainians, as the battle extends to fighting the country\'s high levels of hepatitis C. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 19.10.2023
Tilføjet 19.10.2023
ECDC
ECDC Communicable Disease Threats Report, 13.10.2023
Tilføjet 13.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Læs mereECDC
ECDC COVID-19 updates, 13.10.2023
Tilføjet 13.10.2023
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 8-14 October 2023 and includes updates on hepatitis A, influenza A(H5N1), COVID-19, the Rugby World Cup 2023, West Nile virus, measles and diphtheria.
Læs mereSarah van de Berg, Tanja Charles, Achim Dörre, Katharina Katz and Stefanie Böhm
Eurosurveillance latest updates, 13.10.2023
Tilføjet 13.10.2023
BackgroundUnprecedented non-pharmaceutical interventions to control the COVID-19 pandemic also had an effect on other infectious diseases. AimWe aimed to determine their impact on transmission and diagnosis of notifiable diseases other than COVID-19 in Bavaria, Germany, in 2020 and 2021. MethodsWe compared weekly cases of 15 notifiable infectious diseases recorded in Bavaria between 1 January 2016 and 31 December 2021 in time series analyses, median age and time-to-diagnosis using Wilcoxon rank sum test and hospitalisation rates using univariable logistic regression during three time periods: pre-pandemic (weeks 1 2016–9 2020), pandemic years 1 (weeks 10–52 2020) and 2 (2021). ResultsWeekly case numbers decreased in pandemic year 1 for all diseases assessed except influenza, Lyme disease and tick-borne encephalitis; markedly for norovirus gastroenteritis (IRR = 0.15; 95% CI: 0.12–0.20) and pertussis (IRR = 0.22; 95% CI: 0.18–0.26). In pandemic year 2, influenza (IRR = 0.04; 95% CI: 0.02–0.09) and pertussis (IRR = 0.11; 95% CI: 0.09–0.14) decreased markedly, but also chickenpox, dengue fever, Haemophilus influenzae invasive infection, hepatitis C, legionellosis, noro- and rotavirus gastroenteritis and salmonellosis. For enterohaemorrhagic Escherichia coli infections, median age decreased in pandemic years 1 and 2 (4 years, interquartile range (IQR): 1–32 and 3 years, IQR: 1–18 vs 11 years, IQR: 2–42); hospitalisation proportions increased in pandemic year 1 (OR = 1.60; 95% CI: 1.08–2.34). ConclusionReductions for various infectious diseases and changes in case characteristics in 2020 and 2021 indicate reduced transmission of notifiable diseases other than COVID-19 due to interventions and under-detection.
Læs mereMedscape Infectious Diseases, 27.09.2023
Tilføjet 27.09.2023
Alcohol use at any level was not associated with a lower likelihood of responding to direct-acting antiviral therapy for chronic hepatitis C virus infection. Medscape Medical News
Læs mereBerta Grau-Pujol, João Vieira Martins, Isabel Goncalves, Fernanda Rodrigues, Rita de Sousa, Dina Oliveira, Joana Bettencourt, Diana Mendes, Inês Mateus de Cunha, Sara Pocinho, Ana Firme, Benvinda Estela dos Santos, André Peralta Santos, Maria João Albuquerque, Pedro Pinto-Leite, Rui Tato Marinho and Paula Vasconcelos
Eurosurveillance latest updates, 22.09.2023
Tilføjet 22.09.2023
On 5 April 2022, the United Kingdom reported an increase of cases of severe acute hepatitis of unknown aetiology in children, several needing hospitalisation and some required liver transplant or died. Thereafter, 35 countries reported probable cases, almost half of them in Europe. Facing the alert, on 28 April, Portugal created a multidisciplinary Task Force (TF) for rapid detection of probable cases and response. The experts of the TF came from various disciplines: clinicians, laboratory experts, epidemiologists, public health experts and national and international communication. Moreover, Portugal adopted the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO) case definition and recommendations. By 31 December 2022, 28 probable cases of severe acute hepatitis of unknown aetiology were reported: 16 male and 17 aged under 2 years. Of these cases, 23 were hospitalised but none required liver transplant or died. Adenovirus was detected from nine of 26 tested cases. No association was observed between adenovirus infection and hospital admission after adjusting for age, sex and region in a binomial regression model. The TF in Portugal may have contributed to increase awareness among clinicians, enabling early detection and prompt management of the outbreak.
Læs mereMedscape Infectious Diseases, 23.08.2023
Tilføjet 23.08.2023
Mortality rates remain substantially elevated after successful treatment of hepatitis C infection in the era of interferon-free antiviral therapy, a study of over 20,000 patients has found. Medscape Medical News
Læs mereSandra Bivegete, Anna L McNaughton, Adam Trickey, Zak Thornton, Becky Scanlan, Aaron G Lim, Lina Nerlander, Hannah Fraser, Josephine G Walker, Matthew Hickman, Peter Vickerman, Helen Johnson, Erika Duffell, Ellen Brooks-Pollock and Hannah Christensen
Eurosurveillance latest updates, 28.07.2023
Tilføjet 28.07.2023
BackgroundThe burden of chronic hepatitis B virus (HBV) varies across the European Union (EU) and European Economic Area (EEA). AimWe aimed to update the 2017 HBV prevalence estimates in EU/EEA countries and the United Kingdom for 2018 to 2021. MethodsWe undertook a systematic review, adding to HBV prevalence estimates from an existing (2005–2017) database. Databases were searched for original English-language research articles including HBV surface antigen prevalence estimates among the general population, pregnant women, first-time blood donors (FTB), men who have sex with men (MSM), migrants and people in prison. Country experts contributed grey literature data. Risk of bias was assessed using a quality assessment framework. FindingsThe update provided 147 new prevalence estimates across the region (updated total n = 579). Median HBV prevalence in the general population was 0.5% and the highest was 3.8% (Greece). Among FTB, the highest prevalence was 0.8% (Lithuania). Estimates among pregnant women were highest in Romania and Italy (5.1%). Among migrants, the highest estimate was 31.7% (Spain). Relative to 2017 estimates, median prevalence among pregnant women decreased by 0.5% (to 0.3%) and increased by 0.9% (to 5.8%) among migrants. Among MSM, the highest estimate was 3.4% (Croatia). Prevalence among people in prison was highest in Greece (8.3%) and the median prevalence increased by 0.6% (to 2.1%). ConclusionsThe HBV prevalence is low in the general population and confined to risk populations in most European countries with some exceptions. Screening and treatment should be targeted to people in prison and migrants.
Læs mereNino Khetsuriani, Amiran Gamkrelidze, Shaun Shadaker, Maia Tsereteli, Maia Alkhazashvili, Nazibrola Chitadze, Irina Tskhomelidze, Lia Gvinjilia, Francisco Averhoff, Gavin Cloherty, Qian An, Giorgi Chakhunashvili, Jan Drobeniuc, Paata Imnadze, Khatuna Zakhashvili and Paige A Armstrong
Eurosurveillance latest updates, 28.07.2023
Tilføjet 28.07.2023
BackgroundGeorgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. AimWe aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. MethodsThis nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers. ResultsAmong 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds. ConclusionsHepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.
Læs mereJosephine G. Walker, Irina Tskhomelidze, Shaun Shadaker, Maia Tsereteli, Senad Handanagic, Paige A. Armstrong, Amiran Gamkrelidze and Peter Vickerman
Eurosurveillance latest updates, 28.07.2023
Tilføjet 28.07.2023
BackgroundBetween May 2015 and February 2022, 77,168 hepatitis C virus (HCV)-infected people in Georgia have been treated through an HCV elimination programme. To project the programme’s long-term impacts, an HCV infection model was initially developed, based on data from surveys among people who inject drugs and a national serosurvey in 2015. AimAccounting for follow-up surveys in 2021, we validate and update projections of HCV infection prevalence and incidence. MethodWe assessed the initial model projections’ accuracy for overall prevalence, by age, sex, and among people who ever injected drugs, compared with 2021 serosurvey data. We used 2021 results to weight model fits and to recalculate the national programme’s impact leading up to March 2022 on HCV infection incidence rates. Cases and deaths averted were estimated. The impact of reduced treatment rates during the COVID-19 pandemic was assessed. ResultsThe original model overpredicted adult (≥ 18 years old) chronic HCV infection prevalence for 2021 (2.7%; 95% credible interval (CrI): 1.9–3.5%) compared with a 2021 serosurvey (1.8%; 95% confidence interval (CI): 1.3–2.4%). Weighted model projections estimated a 60% decrease in HCV infection incidence by March 2022, with an absolute incidence of 66 (95% CrI: 34–131) per 100,000 person-years (overall population). Between May 2015 and March 2022, 9,186 (95% CrI: 5,396–16,720) infections and 842 (95% CrI: 489–1,324) deaths were averted. The COVID-19 pandemic resulted in 13,344 (95% CrI: 13,236–13,437) fewer treatments and 438 (95% CrI: 223-744) fewer averted infections by March 2022. ConclusionResults support the programme’s high effectiveness. At current treatment rate (406/month), 90% reductions in prevalence and incidence in Georgia are achievable by 2030.
Læs mereMedscape Infectious Diseases, 28.07.2023
Tilføjet 28.07.2023
Managing alcohol-associated hepatitis following hospital discharge requires treating not only the liver disease but also the underlying alcohol use disorder, says a clinical care review. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 21.07.2023
Tilføjet 21.07.2023
This report describes progress towards hepatitis B control and elimination in the World Health Organization African region.
Læs mereMedscape Infectious Diseases, 15.07.2023
Tilføjet 15.07.2023
World Hepatitis Day is an opportunity to remind people of the impact of viral hepatitis and to offer information that can help prevent, diagnose, and treat these diseases, said one expert. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 14.07.2023
Tilføjet 14.07.2023
Medscape Infectious Diseases, 12.07.2023
Tilføjet 12.07.2023
Patients with hepatitis C virus (HCV) infection face barriers at every step, from diagnosis to accessing breakthrough direct-acting antiviral (DAA) medications, experts say. Medscape Medical News
Læs mereMedscape Infectious Diseases, 8.07.2023
Tilføjet 8.07.2023
Bulevirtide, an investigational, first-in-class hepatitis delta virus entry-inhibitor, significantly reduced viral load and normalized liver enzymes in patients. Medscape Medical News
Læs mereMorbidity and Mortality Weekly Report (MMWR), 1.07.2023
Tilføjet 1.07.2023
Medscape Infectious Diseases, 28.06.2023
Tilføjet 28.06.2023
Vaccination rates for hepatitis B virus are slightly lower among patients with psoriasis than among people without psoriasis. Medscape Medical News
Læs mereAntonio Piralla, Alessandro Borghesi, Amelia Di Comite, Federica Giardina, Guglielmo Ferrari, Simona Zanette, Tiziana Angelica Figar, Micol Angelini, Camilla Pisoni, Antonino Maria Guglielmo Pitrolo, Stefania Paolucci, Francesca Rovida, Isabella Pellicioli, Ezio Bonanomi, Fausto Baldanti and Stefano Ghirardello
Eurosurveillance latest updates, 16.06.2023
Tilføjet 16.06.2023
Echovirus 11 (E11) has recently been associated with a series of nine neonatal cases of severe hepatitis in France. Here, we present severe hepatitis caused by E11 in a pair of twins. In one of the neonates, the clinical picture evolved to fulminant hepatitis. The E11 genome showed 99% nucleotide identity with E11 strains reported in the cases in France. Rapid genome characterisation using next generation sequencing is essential to identify new and more pathogenetic variants.
Læs mereMorbidity and Mortality Weekly Report (MMWR), 1.06.2023
Tilføjet 1.06.2023
This report describes the effectiveness of the Cherokee Nation Health Services hepatitis C elimination program after 5 years.
Læs mereProMED, 27.05.2023
Tilføjet 27.05.2023
Hepatitis A -- United StatesOnce again, cases of hepatitis A in San Diego County are on the rise with 28 reported to date and 18 among people experiencing homelessness. The county usually reports about 2 virus cases monthly. While no single outbreak location has been identified, and no specific food or water source found, cases are being reported above baseline.The county is doing its part to take steps to prevent more spread of the disease. The current increase in cases is likely due to person-to-person transmission
Læs mereProMED, 17.05.2023
Tilføjet 17.05.2023
Hepatitis A -- CanadaVancouver Coastal Health is notifying people who dined at McDonald\'s (3695 Lougheed Hwy, Vancouver) about a possible exposure to hepatitis A on the following dates and times:19 Apr 2023 - 8am to 4pm21 Apr 2023 - 12pm - 7:30pm23 Apr 2023 - 8am - 4pm26 Apr 2023 - 8am - 4pm27 Apr 2023 - 7am - 2pm28 Apr 2023 - 7am - 3pm29 Apr 2023 - 7am - 3pm30 Apr 2023 - 8am - 4pm2 May 2023 - 7am - 3pm4 May 2023 - 8am - 4pm8 May 2023 - 6am - 11am9 May 2023 - 6am - 9amAlthough the
Læs mereProMED, 15.05.2023
Tilføjet 15.05.2023
Hepatitis E -- ChinaHong Kong health officials report investigating a case of human infection of rat Hepatitis E virus (HEV). The case involves a 32-year-old man with underlying illnesses. He was found to have an abnormal liver function during his follow-up in Queen Elizabeth Hospital. The patient is now in stable condition. His blood sample tested positive for rat HEV upon laboratory testing. Epidemiological investigations revealed that the patient resides in Wong Tai Sin. He did not have contact with rodents or
Læs mereProMED, 15.05.2023
Tilføjet 15.05.2023
Hepatitis A -- CanadaHalton Region Public Health has confirmed a case of hepatitis A at a Milton golf club after a food handler at its restaurant tested positive.The agency says the person worked at RattleSnake Point Golf Club Bistro between 20 Apr 2023 and 2 May 2023. The golf club is working closely with the public health agency to contact affected visitors.Hepatitis A is an infectious disease caused by a virus that attacks the liver. According to the agency, symptoms usually happen within 28 to 30 days
Læs mereEttore Severi, Lara Tavoschi, Paloma Carrillo-Santisteve, Therese Westrell, Gaetano Marrone, Johan Giesecke and Pierluigi Lopalco
Eurosurveillance latest updates, 12.05.2023
Tilføjet 12.05.2023
BackgroundEuropean Union/European Economic Area (EU/EEA) countries annually report hepatitis A (HepA) notifications to The European Surveillance System (TESSy). AimTo describe EU/EEA HepA notifications from 2010 to 2019 and identify infection drivers and surveillance improvements. MethodsWe analysed demographic, clinical and transmission information of HepA confirmed cases from TESSy. We stratified countries by population susceptibility profile and performed time-series analysis to describe trends in notification rates, sex distribution and travel history. ResultsTwenty-nine EU/EEA countries reported 139,793 HepA cases. Six eastern EU countries reported > 60% of these cases. EU/EEA notification rate during the study period was 3.2 cases per 100,000 population (range 2.7–5.6). Notifications peaked in 2014 and 2017, with marked differences in case demographic characteristics. Notification trends varied across different country susceptibility groups. In 2017, the proportion of males (74%) and case median age (31 years) increased steeply, while no changes occurred in 2014. Travel history showed seasonal case peaks following the summer. More than 47,000 hospitalisations were reported. Annual case fatality was
Læs mereProMED, 10.05.2023
Tilføjet 10.05.2023
Hepatitis A -- United StatesAt a glance-----------Reported cases: 9States: 3Hospitalizations: 3Deaths: 0CDC, state public health and regulatory officials, and the Food and Drug Administration (FDA) are investigating an outbreak of hepatitis A linked to frozen organic strawberries imported from certain farms located in Baja California, Mexico by a common supplier. Frozen organic strawberries may be sold to a variety of retailers under multiple brand labels. Traceback and epidemiological investigations show
Læs mere